Table 1.
Drugs targeting phosphatidylinositol 3 kinase/Akt/mammalian target of rapamycin pathway
| PI3K/Akt/mTOR subgroups | Agents | Clinical Stage |
| Pan-PI3K inhibitors | XL147 | Phase II |
| BKM120 | Phase III | |
| GDC0941 | Phase II | |
| Rapalogues (mTORC1 inhibitors) | Sirolimus | Phase III |
| Everolimus | Approved | |
| Temsirolimus | Approved | |
| Ridaforolimus | Phase III | |
| mTORC1/2 inhibitors | INK128 | Phase II |
| AZD8055 | Phase I | |
| OSI027 | Phase I | |
| PI3K–mTOR inhibitors | BEZ235 | Phase II |
| XL765 | Phase II | |
| GSK1059615 | Phase I | |
| Isoform-specific PI3K inhibitors | CAL-101 (p110δ) | Phase III |
| INK1117 (p110α) | Phase I | |
| BYL719 (p110α) | Phase II | |
| Akt inhibitors | Perifosine | Phase III |
| MK-2206 | Phase II | |
| GDC0068 | Phase II | |
| GSK690693 | Phase I |
PI3K: Phosphatidylinositol 3 kinase; mTOR: Mammalian target of rapamycin.